President Donald Trump has proposed a 100% tariff on all imported generic drugs, set to take effect in August 2028. The tariff would then double to 200% the following year. The stated goal is to force pharmaceutical companies to move production back to the United States.
The tariff plan
Under the proposal, any generic drug manufactured outside the U.S. would face a 100% import tax starting in August 2028. That rate would jump to 200% in 2029. The plan does not specify which drugs or countries would be affected, but the vast majority of generic medications consumed in the U.S. are made overseas — primarily in India and China.
The proposal is not yet law. It would require either congressional approval or an executive order, depending on the legal authority used. No bill has been introduced, and the White House has not released a detailed implementation timeline beyond the August 2028 start date.
Why reshoring?
The policy's core aim is to bring pharmaceutical manufacturing back to American soil. For decades, U.S. drug companies have shifted production abroad to lower costs, leaving the country reliant on foreign supply chains for many essential medicines. The tariffs are designed to make imported generics so expensive that domestic production becomes the cheaper option.
Supporters argue that reshoring would reduce dependence on foreign suppliers and strengthen national security. Critics warn that the tariffs could raise drug prices for consumers and strain the healthcare system, especially for low-income patients who rely on affordable generics. The proposal does not include any measures to offset potential price increases.
Timeline and political context
The August 2028 start date places the tariff well into the next presidential term. That timing suggests the proposal could serve as a long-term policy goal rather than an immediate action. It also gives pharmaceutical companies several years to adjust their supply chains — if they choose to.
Trump has made reshoring a recurring theme of his economic platform. The generic drug tariff follows similar proposals on other imported goods, including steel and electronics. But the pharmaceutical industry presents unique challenges: building new U.S. manufacturing facilities takes years and requires significant capital investment. The 2029 escalation to 200% adds pressure to move quickly.
The administration has not released further details on how the tariffs would be implemented or whether exceptions would be made for drugs with no domestic alternatives. No legislative text has been drafted, and no hearings have been scheduled. The proposal remains a policy statement — one that will likely face intense debate if it moves toward enactment.
